Abstract:BACKGROUND: Lifestyle modification can forestall diabetes in high-risk people, but the long-term cost-effectiveness is uncertain.OBJECTIVE: To estimate the effects of the lifestyle modification program used in the Diabetes Prevention Program (DPP) on health and economic outcomes.DESIGN: Cost-effectiveness analysis using the Archimedes model.DATA SOURCES: Published basic and epidemiologic studies, clinical trials, and Kaiser Permanente administrative data.TARGET POPULATION: Adults at high risk for diabetes (body mass index >24 kg/m2, fasting plasma glucose level of 5.2725 to 6.9375 mmol/L [95 to 125 mg/dL], 2-hour glucose tolerance test result of 7.77 to 11.0445 mmol/L [140 to 199 mg/dL]).TIME HORIZON: 5 to 30 years.PERSPECTIVE: Patient, health plan, and societal.INTERVENTIONS: No prevention, DPP's lifestyle modification program, lifestyle modification begun after a person develops diabetes, and metformin.MEASUREMENTS: Diagnosis and complications of diabetes.RESULTS OF BASE-CASE ANALYSIS: Compared with no prevention program, the DPP lifestyle program would reduce a high-risk person's 30-year chances of getting diabetes from about 72% to 61%, the chances of a serious complication from about 38% to 30%, and the chances of dying of a complication of diabetes from about 13.5% to 11.2%. Metformin would deliver about one third the long-term health benefits achievable by immediate lifestyle modification. Compared with not implementing any prevention program, the expected 30-year cost/quality-adjusted life-year (QALY) of the DPP lifestyle intervention from the health plan's perspective would be about 143,000 dollars. From a societal perspective, the cost/QALY of the lifestyle intervention compared with doing nothing would be about 62,600 dollars. Either using metformin or delaying the lifestyle intervention until after a person develops diabetes would be more cost-effective, costing about 35,400 dollars or 24,500 dollars per QALY gained, respectively, compared with no program. Compared with delaying the lifestyle program until after diabetes is diagnosed, the marginal cost-effectiveness of beginning the DPP lifestyle program immediately would be about 201,800 dollars.RESULTS OF SENSITIVITY ANALYSIS: Variability and uncertainty deriving from the structure of the model were tested by comparing the model's results with the results of real clinical trials of diabetes and its complications. The most critical element of uncertainty is the effectiveness of the lifestyle program, as expressed by the 95% CI of the DPP study. The most important potentially controllable factor is the cost of the lifestyle program. Compared with no program, lifestyle modification for high-risk people can be made cost-saving over 30 years if the annual cost of the intervention can be reduced to about 100 dollars.LIMITATIONS: Results depend on the accuracy of the model.CONCLUSIONS: Lifestyle modification is likely to have important effects on the morbidity and mortality of diabetes and should be recommended to all high-risk people. The program used in the DPP study may be too expensive for health plans or a national program to implement. Less expensive methods are needed to achieve the degree of weight loss seen in the DPP.

905-P: Simulation Model Estimating Lifetime Health and Economic Outcomes of Prediabetes Screening by One-Hour Plasma Glucose

A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA

1521-P: An Efficacy Evaluation on Prediabetes Management Using a Machine Learning-Based Risk Stratification Approach

Cost-effectiveness of two screening strategies based on Chinese diabetes risk score for pre-diabetes in China

National health and economic impact of a lifestyle program to prevent type 2 diabetes mellitus in Germany: a simulation study

Cost saving analysis of prediabetes intervention modalities in comparison with inaction using Markov state transition model—A multiregional case study

Glucometer analysis of one-hour glucose challenge samples

Exploring Structural Uncertainty in Cost-Effectiveness Modeling of Gestational Diabetes Screening: An Application Example from Norway

1-Hour Post-OGTT Glucose Improves the Early Prediction of Type 2 Diabetes by Clinical and Metabolic Markers

Enhanced Predictive Capability of a 1-Hour Oral Glucose Tolerance Test: A Prospective Population-Based Cohort Study

Assessment of 1-Hour Postload Plasma Glucose, the Metabolic Syndrome, and the Finish Diabetes Risk Score in the Prediction of Type 2 Diabetes

A European Cost-Utility Analysis of the MiniMed™ 780G Advanced Hybrid Closed-Loop System Versus Intermittently Scanned Continuous Glucose Monitoring with Multiple Daily Insulin Injections in People Living with Type 1 Diabetes

An Analytics‐Driven Approach for Optimal Individualized Diabetes Screening

Clinical Outcomes and Cost-Effectiveness of Strategies for Managing People at High Risk for Diabetes

Efficacy of 1‐hour postload plasma glucose as a suitable measurement in predicting type 2 diabetes and diabetes‐related complications: A post hoc analysis of the 30‐year follow‐up of the Da Qing IGT and Diabetes Study

Performance and Costs of Multiple Screening Strategies for Type 2 Diabetes: Two Population-Based Studies in Shanghai, China

Cost-utility of real-time continuous glucose monitoring versus self-monitoring of blood glucose in people with insulin-treated Type II diabetes in France

894-P: The Potential Value of Clustering-Based Type 2 Diabetes Subgroups for Guiding Intensive Treatment: A Maximum Cost-Based Comparison with Threshold-Based Classifications

Comparing the effectiveness and cost-effectiveness of alternative type 2 diabetes monitoring intervals in resource limited settings

Dysglycaemia screening and its prognostic impact in patients with coronary artery disease: experiences from the EUROASPIRE IV and V cohort studies

An economic value of the glycated hemoglobin test in diabetes mellitus type 2 diagnosis